Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible

• Hardy JA , HigginsGA: Alzheimer's disease: the amyloid cascade hypothesis.Science256, 184–185 (1992).
   PubMed Web of Science ®Google Scholar
• Pogacic V , HerrlingP: List of drugs in development for neurodegenerative diseases. Update June 2008.Neurodegener. Dis.6(1–2) , 37–86 (2009).
   PubMed Web of Science ®Google Scholar
• Holmes C , LovestoneS: Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications.Age Ageing32(2) , 200–204 (2003).
   PubMed Web of Science ®Google Scholar
• De Gruttola VG , ClaxP, DeMetsDL et al.: Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.Control Clin. Trials22(5) , 485–502 (2001).
   PubMedGoogle Scholar
• Hunter MP , IsmailN, ZhangX et al.: Detection of microRNA expression in human peripheral blood microvesicles.PLoS ONE3(11) , e3694 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson RJ , LimJW, MoritzRL, MathivananS: Exosomes: proteomic insights and diagnostic potential.Expert Rev. Proteomics6(3) , 267–283 (2009).
   PubMed Web of Science ®Google Scholar
• Modrego PJ : Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment.Curr. Alzheimer Res.3(2) , 161–170 (2006).
   PubMedGoogle Scholar
• Coppola G , KarydasA, RademakersR et al.: Gene expression study on peripheral blood identifies progranulin mutations.Ann. Neurol.64(1) , 92–96 (2008).
   PubMed Web of Science ®Google Scholar
• Grunblatt E , BartlJ, ZehetmayerS et al.: Gene expression as peripheral biomarkers for sporadic Alzheimer's disease.J. Alzheimers Dis.16(3) , 627–634 (2009).
   PubMed Web of Science ®Google Scholar
• Hebert SS , HorreK, NicolaiL et al.: Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expression.Proc. Natl Acad. Sci. USA105(17) , 6415–6420 (2008).
   PubMed Web of Science ®Google Scholar
• Maes OC , ChertkowHM, WangE, SchipperHM: MicroRNA: implications for alzheimer disease and other human CNS disorders.Curr. Genomics10(3) , 154–168 (2009).
   PubMed Web of Science ®Google Scholar
• Schipper HM , MaesOC, ChertkowHM, WangE: MicroRNA expression in Alzheimer blood mononuclear cells.Gene Regul. Syst. Biol.1, 263–274 (2007).
   PubMedGoogle Scholar
• Borovecki F , LovrecicL, ZhouJ et al.: Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.Proc. Natl Acad. Sci. USA102(31) , 11023–11028 (2005).
   PubMed Web of Science ®Google Scholar
• Chagnon YC , RoyMA, BureauA, MeretteC, MaziadeM: Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes.Schizophr. Res.100(1–3) , 281–290 (2008).
   PubMed Web of Science ®Google Scholar
• Chertkow Y , WeinrebO, YoudimMB, SilverH: Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine.Prog. Neuropsychopharmacol. Biol. Psychiatry31(7) , 1356–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Runne H , KuhnA, WildEJ et al.: Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.Proc. Natl Acad. Sci. USA104(36) , 14424–14429 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang HX , ZhaoJP, LvLX et al.: Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia.Neurosci. Lett.438(1) , 1–5 (2008).
   PubMed Web of Science ®Google Scholar
• Altar CA , VawterMP, GinsbergSD: Target identification for CNS diseases by transcriptional profiling.Neuropsychopharmacology34(1) , 18–54 (2009).
   PubMed Web of Science ®Google Scholar
• Corthals GL , WasingerVC, HochstrasserDF, SanchezJC: The dynamic range of protein expression: a challenge for proteomic research.Electrophoresis21(6) , 1104–1115 (2000).
   PubMed Web of Science ®Google Scholar
• Omenn GS , StatesDJ, AdamskiM et al.: Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database.Proteomics5(13) , 3226–3245 (2005).
   PubMed Web of Science ®Google Scholar
• States DJ , OmennGS, BlackwellTW et al.: Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study.Nat. Biotechnol.24(3) , 333–338 (2006).
   PubMed Web of Science ®Google Scholar
• Barelli S , CrettazD, ThadikkaranL, RubinO, TissotJD: Plasma/serum proteomics: pre-analytical issues.Expert Rev. Proteomics4(3) , 363–370 (2007).
   PubMed Web of Science ®Google Scholar
• Hanash SM , PitteriSJ, FacaVM: Mining the plasma proteome for cancer biomarkers.Nature452(7187) , 571–579 (2008).
   PubMed Web of Science ®Google Scholar
• Herosimczyk A , DejeansN, SaydT, OzgoM, SkrzypczakWF, MazurA: Plasma proteome analysis: 2D gels and chips.J. Physiol. Pharmacol.57(Suppl. 7) , 81–93 (2006).
   PubMed Web of Science ®Google Scholar
• Mauri P , ScigelovaM: Multidimensional protein identification technology for clinical proteomic analysis.Clin. Chem. Lab. Med.47(6) , 636–646 (2009).
   PubMed Web of Science ®Google Scholar
• Pernemalm M , LewensohnR, LehtioJ: Affinity prefractionation for MS-based plasma Proteomics Proteomics9(6) , 1420–1427 (2009).
   Google Scholar
• Lovestone S , GuntertA, HyeA, LynhamS, ThambisettyM, WardM: Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers.Expert Rev. Proteomics4(2) , 227–238 (2007).
   PubMed Web of Science ®Google Scholar
• Fukumoto H , TennisM, LocascioJJ, HymanBT, GrowdonJH, IrizarryMC: Age but not diagnosis is the main predictor of plasma amyloid b-protein levels.Arch. Neurol.60(7) , 958–964 (2003).
   PubMed Web of Science ®Google Scholar
• Giedraitis V , SundelofJ, IrizarryMC et al.: The normal equilibrium between CSF and plasma amyloid b levels is disrupted in Alzheimer's disease.Neurosci. Lett.427(3) , 127–131 (2007).
   PubMed Web of Science ®Google Scholar
• Song F , PoljakA, SmytheGA, SachdevP: Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.Brain Res. Rev.61(2) , 69–80 (2009).
   PubMedGoogle Scholar
• Tamaoka A , FukushimaT, SawamuraN et al.: Amyloid β protein in plasma from patients with sporadic Alzheimer's disease.J. Neurol. Sci.141(1–2) , 5–68 (1996).
   Web of Science ®Google Scholar
• Vanderstichele H , Van KerschaverE, HesseCet al.: Standardization of measurement of β-amyloid1–42 in cerebrospinal fluid and plasma.Amyloid7(4) , 245–258 (2000).
   PubMed Web of Science ®Google Scholar
• Lewczuk P , KornhuberJ, VandersticheleH et al.: Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.Neurobiol. Aging29(6) , 812–818 (2008).
   PubMed Web of Science ®Google Scholar
• Schupf N , TangMX, FukuyamaH et al.: Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease.Proc. Natl Acad. Sci. USA105(37) , 14052–14057 (2008).
   PubMed Web of Science ®Google Scholar
• van Oijen M , HofmanA, SoaresHD, KoudstaalPJ, BretelerMM: Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study.Lancet Neurol.5(8) , 655–660 (2006).
   PubMed Web of Science ®Google Scholar
• Graff-Radford NR , CrookJE, LucasJ et al.: Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.Arch. Neurol.64(3) , 354–362 (2007).
   PubMedGoogle Scholar
• Sundelof J , GiedraitisV, IrizarryMC et al.: Plasma β amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.Arch. Neurol.65(2) , 256–263 (2008).
   PubMedGoogle Scholar
• Lambert JC , Schraen-MaschkeS, RichardF et al.: Association of plasma amyloid β with risk of dementia: the prospective Three-City Study.Neurology73(11) , 847–853 (2009).
   PubMed Web of Science ®Google Scholar
• Locascio JJ , FukumotoH, YapL et al.: Plasma amyloid b-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease.Arch. Neurol.65(6) , 776–785 (2008).
   PubMedGoogle Scholar
• Kester MI , VerweyNA, van ElkEJ, BlankensteinMA, ScheltensP, van der FlierWM: Progression from MCI to AD: Predictive value of CSF Aβ42 is modified by APOE genotype. Neurobiol. Aging (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Fleisher AS , RamanR, SiemersER et al.: Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease.Arch. Neurol.65(8) , 1031–1038 (2008).
   PubMedGoogle Scholar
• Roher AE , EshCL, KokjohnTA et al.: Amyloid β peptides in human plasma and tissues and their significance for Alzheimer's disease.Alzheimers Dement.5(1) , 18–29 (2009).
   PubMed Web of Science ®Google Scholar
• Matsumoto Y , YanaseD, Noguchi-ShinoharaM, OnoK, YoshitaM, YamadaM: Blood–brain barrier permeability correlates with medial temporal lobe atrophy but not with Amyloid-β protein transport across the blood–brain barrier in Alzheimer's disease.Dement. Geriatr. Cogn. Disord.23(4) , 241–245 (2007).
   PubMed Web of Science ®Google Scholar
• Mehta PD , PirttilaT, MehtaSP, SersenEA, AisenPS, WisniewskiHM: Plasma and cerebrospinal fluid levels of amyloid β proteins 1–40 and 1–42 in Alzheimer disease.Arch. Neurol.57(1) , 100–105 (2000).
   PubMedGoogle Scholar
• Mehta PD , PirttilaT, PatrickBA, BarshatzkyM, MehtaSP: Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.Neurosci. Lett.304(1–2) , 102–106 (2001).
   PubMed Web of Science ®Google Scholar
• Pesaresi M , LovatiC, BertoraP et al.: Plasma levels of β-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment.Neurobiol. Aging27(6) , 904–905 (2006).
   PubMed Web of Science ®Google Scholar
• Kawarabayashi T , ShojiM: Plasma biomarkers of Alzheimer's disease.Curr. Opin. Psychiatry21(3) , 260–267 (2008).
   PubMed Web of Science ®Google Scholar
• Clarke R , SmithAD, JobstKA, RefsumH, SuttonL, UelandPM: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease.Arch. Neurol.55(11) , 1449–1455 (1998).
   PubMedGoogle Scholar
• Van Dam F , Van GoolWA: Hyperhomocysteinemia and Alzheimer's disease: a systematic review. Arch. Gerontol. Geriatr.48(3) , 425–430 (2009).
   PubMed Web of Science ®Google Scholar
• Helfand M , BuckleyDI, FreemanM et al.: Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the US Preventive Services Task Force.Ann. Intern. Med.151(7) , 496–507 (2009).
   PubMed Web of Science ®Google Scholar
• Lepara O , AlajbegovicA, ZaciragicA et al.: Elevated serum homocysteine level is not associated with serum C-reactive protein in patients with probable Alzheimer's disease.J. Neural. Transm.116(12) , 1651–1656 (2009).
   PubMed Web of Science ®Google Scholar
• Engelhart MJ , GeerlingsMI, MeijerJ et al.: Inflammatory proteins in plasma and the risk of dementia: the rotterdam study.Arch. Neurol.61(5) , 668–672 (2004).
   PubMedGoogle Scholar
• Kravitz BA , CorradaMM, KawasCH: Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old.Alzheimers Dement.5(4) , 318–323 (2009).
   PubMed Web of Science ®Google Scholar
• Licastro F , ChiappelliM, RuscicaM, CarnelliV, CorsiMM: Altered cytokine and acute phase response protein levels in the blood of children with Down's syndrome: relationship with dementia of Alzheimer's type.Int. J. Immunopathol. Pharmacol.18(1) , 165–172 (2005).
   PubMed Web of Science ®Google Scholar
• Mancinella A , MancinellaM, CarpinteriG et al.: Is there a relationship between high C-reactive protein (CRP) levels and dementia?Arch. Gerontol. Geriatr.49(Suppl. 1) , 185–194 (2009).
   PubMed Web of Science ®Google Scholar
• Roberts RO , GedaYE, KnopmanDS et al.: Association of C-reactive protein with mild cognitive impairment.Alzheimers Dement.5(5) , 398–405 (2009).
   PubMed Web of Science ®Google Scholar
• Xu G , ZhouZ, ZhuW, FanX, LiuX: Plasma C-reactive protein is related to cognitive deterioration and dementia in patients with mild cognitive impairment.J. Neurol. Sci.284(1–2) , 77–80 (2009).
   PubMed Web of Science ®Google Scholar
• Jefferson AL , MassaroJM, WolfPA et al.: Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study.Neurology68(13) , 1032–1038 (2007).
   PubMed Web of Science ®Google Scholar
• Tan ZS , BeiserAS, VasanRS et al.: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.Neurology68(22) , 1902–1908 (2007).
   PubMed Web of Science ®Google Scholar
• Ravaglia G , FortiP, MaioliF et al.: Risk factors for dementia: data from the Conselice study of brain aging.Arch. Gerontol. Geriatr.44(Suppl. 1) , 311–320 (2007).
   PubMed Web of Science ®Google Scholar
• Hye A , KerrF, ArcherN et al.: Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.Neurosci. Lett.373(1) , 1–4 (2005).
   PubMed Web of Science ®Google Scholar
• Zenzmaier C , MarksteinerJ, KieferA, BergerP, HumpelC: Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients.J. Neurochem.110(2) , 653–661 (2009).
   PubMed Web of Science ®Google Scholar
• Marksteiner J , HumpelC: Glycogen-synthase kinase-3b is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment.Exp. Gerontol.44(6–7) , 370–371 (2009).
   PubMed Web of Science ®Google Scholar
• Ray S , BritschgiM, HerbertC et al.: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.Nat. Med.13(11) , 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Marksteiner J , KemmlerG, WeissEM et al.: Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease.Neurobiol. Aging (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Soares HD , ChenY, SabbaghM, RohrerA, SchrijversE, BretelerM: Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels.Ann. NY Acad. Sci.1180, 56–67 (2009).
   PubMed Web of Science ®Google Scholar
• Gomez Ravetti M , MoscatoP: Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease.PLoS ONE3(9) , e3111 (2008).
   PubMed Web of Science ®Google Scholar
• Hye A , LynhamS, ThambisettyM et al.: Proteome-based plasma biomarkers for Alzheimer's disease.Brain129(Pt 11) , 3042–3050 (2006).
   PubMed Web of Science ®Google Scholar
• Thambisetty M , HyeA, FoyC et al.: Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.J. Neurol.255(11) , 1712–1720 (2008).
   PubMed Web of Science ®Google Scholar
• Brooks JO 3rd , YesavageJA: Identification of fast and slow decliners in Alzheimer disease: a different approach. Alzheimer Dis. Assoc. Disord.9(Suppl. 1) , S19–S25 (1995).
   PubMed Web of Science ®Google Scholar
• Kraemer HC , TinklenbergJ, YesavageJA: ‘How far’ vs ‘how fast’ in Alzheimer's disease. The question revisited.Arch. Neurol.51(3) , 275–279 (1994).
   PubMedGoogle Scholar
• Thambisetty M , SimmonsA, VelayudhanL et al.: Clusterin, an amyloid chaperone protein in plasma, is associated with severity, pathology and progression in Alzheimer's disease.Arch. Gen. Psychiatry (2010) (In press).
   PubMedGoogle Scholar
• Lopez MF , MikulskisA, KuzdzalS et al.: High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures.Clin. Chem.51(10) , 1946–1954 (2005).
   PubMed Web of Science ®Google Scholar
• German DC , GurnaniP, NandiA et al.: Serum biomarkers for Alzheimer's disease: proteomic discovery.Biomed. Pharmacother.61(7) , 383–389 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang R , BarkerL, PinchevD et al.: Mining biomarkers in human sera using proteomic tools.Proteomics4(1) , 244–256 (2004).
   PubMed Web of Science ®Google Scholar
• Cutler P , AkuffoEL, BodnarWM et al.: Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma.Proteomics Clin. Appl.2(4) , 467–477 (2008).
   PubMed Web of Science ®Google Scholar
• Butterfield DA , GalvanV, LangeMB et al.: In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid b-peptide of APP.Free Radic. Biol. Med. (2009) (In Press).
   PubMed Web of Science ®Google Scholar
• Choi J , MalakowskyCA, TalentJM, ConradCC, GracyRW: Identification of oxidized plasma proteins in Alzheimer's disease.Biochem. Biophys. Res. Commun.293(5) , 1566–1570 (2002).
   PubMed Web of Science ®Google Scholar
• Sultana R , ButterfieldDA: Role of oxidative stress in the progression of Alzheimer's disease.J. Alzheimers Dis. (2009) (Epub ahead of print).
   Google Scholar
• Akuffo EL , DavisJB, FoxSM et al.: The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone.Biomarkers13(6) , 618–636 (2008).
   PubMed Web of Science ®Google Scholar
• Mhyre TR , LoyR, TariotPN et al.: Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.Neurobiol. Aging29(11) , 1631–1643 (2008).
   PubMed Web of Science ®Google Scholar
• Mueller SG , WeinerMW, ThalLJ et al.: The Alzheimer's disease neuroimaging initiative.Neuroimaging Clin. N. Am.15(4) , 869–877, xi–xii (2005).
   PubMed Web of Science ®Google Scholar
• Lovestone S , FrancisP, KloszewskaI et al.: AddNeuroMed – the European collaboration for the discovery of novel biomarkers for Alzheimer's disease.Ann. NY Acad. Sci.1180, 36–46 (2009).
   PubMed Web of Science ®Google Scholar
• Anstey KJ , LipnickiDM, LowLF: Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis.Am. J. Geriatr. Psychiatry16(5) , 343–354 (2008).
   PubMed Web of Science ®Google Scholar
• Solomon A , KareholtI, NganduT et al.: Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study.Neurology68(10) , 751–756 (2007).
   PubMed Web of Science ®Google Scholar
• Kolsch H , HeunR, KerksiekA, BergmannKV, MaierW, LutjohannD: Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients.Neurosci. Lett.368(3) , 303–308 (2004).
   PubMed Web of Science ®Google Scholar
• Vaya J , SchipperHM: Oxysterols, cholesterol homeostasis, and Alzheimer disease.J. Neurochem.102(6) , 1727–1737 (2007).
   PubMed Web of Science ®Google Scholar
• Siest G , BertrandP, QinB et al.: Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group.Clin. Chem. Lab. Med.38(8) , 721–730 (2000).
   PubMed Web of Science ®Google Scholar
• Slooter AJ , de KnijffP, HofmanAet al.: Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci. Lett.248(1) , 21–24 (1998).
   PubMed Web of Science ®Google Scholar
• Taddei K , ClarnetteR, GandySE, MartinsRN: Increased plasma apolipoprotein E (ApoE) levels in Alzheimer's disease.Neurosci. Lett.223(1) , 29–32 (1997).
   PubMed Web of Science ®Google Scholar
• Schiele F , De BacquerD, Vincent-ViryMet al.: Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis152(2) , 475–488 (2000).
   PubMed Web of Science ®Google Scholar
• Vincent-Viry M , SchieleF, GueguenR, BohnetK, VisvikisS, SiestG: Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study.Clin. Chem.44(5) , 957–965 (1998).
   PubMed Web of Science ®Google Scholar
• Pratico D , ClarkCM, LeeVM, TrojanowskiJQ, RokachJ, FitzGeraldGA: Increased 8,12-iso-iPF2α-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity.Ann. Neurol.48(5) , 809–812 (2000).
   PubMed Web of Science ®Google Scholar
• Montine TJ , QuinnJ, KayeJ, MorrowJD: F2-isoprostanes as biomarkers of late-onset Alzheimer's disease.J. Mol. Neurosci.33(1) , 114–119 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshida Y , YoshikawaA, KinumiT et al.: Hydroxyoctadecadienoic acid and oxidatively modified peroxiredoxins in the blood of Alzheimer's disease patients and their potential as biomarkers.Neurobiol. Aging30(2) , 174–185 (2009).
   PubMed Web of Science ®Google Scholar
• van Oijen M , WittemanJC, HofmanA, KoudstaalPJ, BretelerMM: Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia.Stroke36(12) , 2637–2641 (2005).
   PubMed Web of Science ®Google Scholar
• Xu G , ZhangH, ZhangS, FanX, LiuX: Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment.Int. J. Clin. Pract.62(7) , 1070–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Bots ML , BretelerMM, vanKooten Fet al.: Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study. Haemostasis28(3–4) , 216–222 (1998).
   PubMedGoogle Scholar
• Wilson CJ , CohenHJ, PieperCF: Cross-linked fibrin degradation products (D-dimer), plasma cytokines, and cognitive decline in community-dwelling elderly persons.J. Am. Geriatr. Soc.51(10) , 1374–1381 (2003).
   PubMed Web of Science ®Google Scholar
• Ravaglia G , FortiP, MaioliF et al.: Homocysteine and folate as risk factors for dementia and Alzheimer disease.Am. J. Clin. Nutr.82(3) , 636–643 (2005).
   PubMed Web of Science ®Google Scholar
• Seshadri S , BeiserA, SelhubJ et al.: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.N. Engl. J. Med.346(7) , 476–483 (2002).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA , TangMX, SheaS, MillerJ, GreenR, MayeuxR: Plasma homocysteine levels and risk of Alzheimer disease.Neurology62(11) , 1972–1976 (2004).
   PubMed Web of Science ®Google Scholar

Website

• Human Proteome Organization www.hupo.org
   Google Scholar